MCID: CRB138
MIFTS: 47

Core Binding Factor Acute Myeloid Leukemia malady

Download this MalaCard

Summaries for Core Binding Factor Acute Myeloid Leukemia

About this section


Fully expand this MalaCard
Genetics Home Reference:21 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary: Core Binding Factor Acute Myeloid Leukemia, also known as leukemia, myelocytic, acute, is related to acute myeloid leukemia and myeloid leukemia. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), and among its related pathways are Hematopoietic cell lineage and Development FGFR signaling pathway. The drugs cyclophosphamide and etoposide and the compounds tandutinib and pkc 412 have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone, and related mouse phenotypes are craniofacial and liver/biliary system.

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

About this section

Core Binding Factor Acute Myeloid Leukemia, Aliases & Descriptions:

Name: Core Binding Factor Acute Myeloid Leukemia 21
Leukemia, Myelocytic, Acute 62
Cbf Acute Myeloid Leukemia 21
 
Core-Binding Factor Aml 21
Cbf-Aml 21


Related Diseases for Core Binding Factor Acute Myeloid Leukemia

About this section

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show all 46)
idRelated DiseaseScoreTop Affiliating Genes
1acute myeloid leukemia32.0KIT, RUNX1, FLT3
2myeloid leukemia30.9CBFB, RUNX1, FLT3, JAK2, KIT, HRAS
3systemic mastocytosis30.8KIT, JAK2
4leukemia30.4KIT, HRAS, CBFB, JAK2, FLT3, RUNX2
5hematopoietic stem cell transplantation10.5
6mastocytosis10.5
7myeloid sarcoma10.3FLT3, KIT
8mast cell neoplasm10.3FLT3, KIT
9leukemia, acute lymphoblastic 310.3FLT3, KIT
10myelofibrosis10.2JAK2
11gastrointestinal stromal tumor10.2KIT, FLT3
12neurofibromatosis10.2KIT, HRAS
13acute myelomonocytic leukemia10.2RUNX1, CBFB
14acute lymphoblastic leukemia, childhood10.1RUNX1, FLT3
15bone marrow cancer10.1FLT3, JAK2
16hemorrhagic thrombocythemia10.1KIT, JAK2
17acute promyelocytic leukemia10.1RUNX1, FLT3
18acute myeloid leukemia, adult10.1RUNX1, FLT3, KIT
19thyroid hurthle cell carcinoma10.1HRAS, FLT3
20thrombocytosis10.0FLT3, JAK2
21kidney cancer10.0KIT, HRAS, FLT3
22juvenile myelomonocytic leukemia10.0RUNX1, HRAS, FLT3
23eosinophilia10.0JAK2, CBFB
24cleidocranial dysplasia9.9RUNX1, RUNX2, CBFB
25polycythemia vera9.9FLT3, JAK2, KIT
26hypersensitivity reaction type ii disease9.9HRAS, FLT3, RUNX1
27retinoblastoma9.9RUNX1, RUNX2, HRAS
28down syndrome9.9FLT3, RUNX1, JAK2
29prostate cancer9.8JAK2, FLT3, HRAS
30stomach cancer9.8CBFB, RUNX1, RUNX2
31glioblastoma9.8JAK2, KIT, HRAS
32refractory anemia9.7KIT, JAK2, FLT3, RUNX1
33pdgfrb-associated chronic eosinophilic leukemia9.7JAK2, RUNX1, FLT3, KIT
34melanoma9.7HRAS, KIT, JAK2, FLT3
35sarcoma9.7RUNX1, JAK2, KIT, HRAS
36ovarian cancer9.7HRAS, RUNX1, JAK2
37precursor t-cell acute lymphoblastic leukemia9.7RUNX1, FLT3, JAK2, HRAS
38rheumatoid arthritis9.6RUNX1, RUNX2, JAK2
39myelodysplastic syndromes9.5KIT, CBFB, JAK2, RUNX1, FLT3
40colonic benign neoplasm9.5JAK2, RUNX1, HRAS
41hematologic cancer9.5JAK2, KIT, HRAS, FLT3, RUNX1
42burkitt's lymphoma9.4FLT3, RUNX2, RUNX1, HRAS, JAK2
43chronic myeloid leukemia9.3HRAS, KIT, RUNX1, CBFB, JAK2, FLT3
44acute leukemia9.3CBFB, KIT, JAK2, HRAS, RUNX1, FLT3
45acute lymphoblastic leukemia9.3CBFB, HRAS, KIT, RUNX1, FLT3, JAK2
46breast cancer9.0RUNX2, RUNX1, JAK2, CBFB, KIT, HRAS

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to core binding factor acute myeloid leukemia

Symptoms for Core Binding Factor Acute Myeloid Leukemia

About this section

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

About this section

Drug clinical trials:

Search ClinicalTrials for Core Binding Factor Acute Myeloid Leukemia

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Inferred drug relations via UMLS62/NDF-RT40:

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

About this section

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

About this section

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

32
Myeloid, Bone marrow, Bone, Eye

Animal Models for Core Binding Factor Acute Myeloid Leukemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

36 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.6RUNX2, CBFB, KIT, HRAS
2MP:00053708.6KIT, CBFB, RUNX2, RUNX1
3MP:00028738.2HRAS, KIT, JAK2, RUNX1
4MP:00030128.2RUNX1, RUNX2, CBFB, KIT, HRAS
5MP:00053888.2RUNX1, RUNX2, CBFB, KIT, HRAS
6MP:00053858.1RUNX1, RUNX2, CBFB, KIT, HRAS
7MP:00053798.0RUNX2, JAK2, KIT, HRAS
8MP:00053808.0RUNX1, JAK2, CBFB, KIT
9MP:00036318.0RUNX1, RUNX2, CBFB, KIT, HRAS
10MP:00020067.7HRAS, KIT, CBFB, JAK2, FLT3, RUNX1
11MP:00053977.5RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
12MP:00053877.5RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
13MP:00053907.5RUNX1, RUNX2, JAK2, CBFB, KIT, HRAS
14MP:00107717.4RUNX1, RUNX2, JAK2, CBFB, KIT, HRAS
15MP:00053847.4RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
16MP:00053787.1RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
17MP:00053767.0RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT
18MP:00107687.0RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT

Publications for Core Binding Factor Acute Myeloid Leukemia

About this section

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show all 43)
idTitleAuthorsYear
1
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. (25348871)
2014
2
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. (24793731)
2014
3
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. (25088818)
2014
4
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. (25006122)
2014
5
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). (24844781)
2014
6
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. (24972769)
2014
7
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. (23783394)
2013
8
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. (23053179)
2013
9
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. (23321257)
2013
10
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. (23677335)
2013
11
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? (24319183)
2013
12
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. (23266036)
2013
13
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. (23716553)
2013
14
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. (23646898)
2013
15
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. (24226631)
2013
16
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. (22145956)
2012
17
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. (22234698)
2012
18
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. (21928314)
2012
19
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. (22886749)
2012
20
Treatment strategies in patients with core-binding factor acute myeloid leukemia. (21755276)
2011
21
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. (21715005)
2011
22
Core binding factor acute myeloid leukemia (CBF-AML) in MAcxico: a single institution experience. (21574542)
2011
23
Core-binding factor acute myeloid leukemia. (22032582)
2011
24
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. (20709669)
2010
25
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? (19468270)
2009
26
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. (19644024)
2009
27
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. (19126873)
2009
28
Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. (19603346)
2009
29
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. (18981008)
2008
30
Core binding factor acute myeloid leukemia. (18692691)
2008
31
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. (18297529)
2008
32
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. (18940681)
2008
33
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. (18841055)
2008
34
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. (17960171)
2008
35
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. (17485551)
2007
36
Core binding factor acute myeloid leukemia. (16728942)
2006
37
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). (16598313)
2006
38
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. (16015387)
2005
39
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. (16110030)
2005
40
Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. (15068897)
2004
41
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. (15289486)
2004
42
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (15124687)
2004
43
Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. (14695213)
2003

Variations for Core Binding Factor Acute Myeloid Leukemia

About this section

Expression for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section
Expression patterns in normal tissues for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards/GeneDecks:

(show all 38)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.7KIT, FLT3
2
Show member pathways
Development Flt3 signaling60
9.5FLT3, HRAS
3
Show member pathways
9.4RUNX1, HRAS
49.4RUNX2, CBFB
59.3HRAS, RUNX2
69.3RUNX2, RUNX1
7
Show member pathways
9.2FLT3, KIT, HRAS
8
Show member pathways
9.2FLT3, KIT, HRAS
9
Show member pathways
9.2HRAS, KIT, FLT3
10
Show member pathways
9.2FLT3, KIT, HRAS
11
Show member pathways
9.1HRAS, JAK2
129.1JAK2, HRAS
139.1JAK2, HRAS
149.1JAK2, HRAS
159.1HRAS, JAK2
16
Show member pathways
Immune response IL 3 activation and signaling pathway60
9.1HRAS, JAK2
17
Show member pathways
EPO Receptor Signaling37
EPO signaling pathway37
9.1HRAS, JAK2
18
Show member pathways
9.1HRAS, JAK2
19
Show member pathways
MAPK Cascade37
Immune response Oncostatin M signaling via MAPK in human cells60
Oncostatin M Signaling Pathway37
9.1JAK2, HRAS
209.1HRAS, JAK2
219.0JAK2, RUNX2
228.9FLT3, RUNX2, RUNX1
238.9KIT, JAK2, FLT3
24
Show member pathways
8.8JAK2, KIT, HRAS
25
Show member pathways
8.8HRAS, KIT, JAK2
26
Show member pathways
Signaling events mediated by Stem cell factor receptor (c-Kit)37
8.8HRAS, KIT, JAK2
27
Show member pathways
Development EDNRB signaling60
Development ACM2 and ACM4 activation of ERK60
Cell adhesion Integrin inside out signaling60
Development G Proteins mediated regulation MARK ERK signaling60
Signal transduction IP3 signaling60
Development Angiotensin signaling via PYK260
Development EPO induced MAPK pathway60
8.8JAK2, KIT, HRAS
28
Show member pathways
8.8HRAS, KIT, JAK2
298.8JAK2, KIT, HRAS
30
Show member pathways
8.7FLT3, JAK2, HRAS
31
Show member pathways
Signal transduction PTEN pathway60
8.6HRAS, KIT, FLT3, RUNX1
328.6HRAS, KIT, FLT3, RUNX1
338.5RUNX2, JAK2, HRAS
34
Show member pathways
8.3FLT3, JAK2, KIT, HRAS
35
Show member pathways
8.3FLT3, JAK2, KIT, HRAS
36
Show member pathways
8.3FLT3, JAK2, KIT, HRAS
37
Show member pathways
8.3HRAS, KIT, JAK2, FLT3
38
Show member pathways
8.3FLT3, JAK2, KIT, HRAS

Compounds for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Compounds related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards/GeneDecks:

(show all 43)
idCompoundScoreTop Affiliating Genes
1tandutinib4410.1KIT, FLT3
2pkc 4124410.0KIT, FLT3
3ag-12964410.0KIT, FLT3
4su54164410.0KIT, FLT3
5ponatinib50 1111.0KIT, FLT3
6sunitinib44 50 1112.0KIT, FLT3
717-(allylamino)-17-demethoxygeldanamycin449.8KIT, FLT3
8methylcellulose449.8KIT, FLT3
9sorafenib44 50 1111.7FLT3, KIT
10beta-tyrosine449.7JAK2, KIT
11lestaurtinib44 6110.6JAK2, FLT3
12hydroxyurea44 50 1111.3KIT, JAK2
13valine449.1JAK2, KIT, HRAS
14herbimycin a44 6110.1HRAS, JAK2, FLT3
15arsenite44 2410.1JAK2, FLT3, RUNX1
16phenylalanine449.1JAK2, KIT, HRAS
17doxorubicin44 50 1111.0RUNX1, FLT3, KIT, HRAS
1812-o-tetradecanoylphorbol 13-acetate448.9HRAS, JAK2, RUNX1
19gp 130448.8FLT3, JAK2, KIT, HRAS
20imatinib44 50 1110.8RUNX1, FLT3, JAK2, KIT
21phosphotyrosine448.8HRAS, KIT, JAK2, FLT3
22butyrate448.7RUNX1, RUNX2, JAK2
23rapamycin448.7HRAS, KIT, JAK2, FLT3
24phosphoinositide448.7FLT3, JAK2, KIT, HRAS
25aspartate448.7FLT3, JAK2, KIT, HRAS
26ly294002448.7RUNX2, JAK2, HRAS
27leucine448.7HRAS, KIT, JAK2
28pge2448.6HRAS, JAK2, RUNX2
29atp44 289.6FLT3, JAK2, KIT, HRAS
30pd 98,059448.5HRAS, KIT, JAK2, RUNX2
31steroid448.5RUNX2, JAK2, KIT, HRAS
32nitric oxide44 24 1110.4RUNX2, JAK2, KIT, HRAS
33estrogen448.4RUNX2, JAK2, KIT, HRAS
34cycloheximide448.4KIT, JAK2, RUNX2
35glucose448.3HRAS, KIT, JAK2, RUNX2
36threonine448.2RUNX1, FLT3, JAK2, KIT, HRAS
37thymidine44 249.2HRAS, KIT, JAK2, FLT3, RUNX2
38phosphatidylinositol448.1RUNX2, FLT3, JAK2, KIT, HRAS
39serine448.0RUNX1, RUNX2, JAK2, KIT, HRAS
40oligonucleotide447.6HRAS, KIT, JAK2, FLT3, RUNX2, RUNX1
41vegf447.6RUNX1, RUNX2, FLT3, JAK2, KIT, HRAS
42retinoic acid44 248.6RUNX1, RUNX2, FLT3, JAK2, KIT, HRAS
43tyrosine447.6RUNX1, RUNX2, FLT3, JAK2, KIT, HRAS

GO Terms for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards/GeneDecks:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of phosphatidylinositol 3-kinase activityGO:0435529.9KIT, FLT3
2embryonic hemopoiesisGO:0351629.8KIT, RUNX1
3definitive hemopoiesisGO:0602169.8CBFB, RUNX1
4myeloid cell differentiationGO:0300999.8CBFB, RUNX1
5stem cell differentiationGO:0488639.8RUNX2, KIT
6T cell differentiationGO:0302179.7KIT, RUNX2
7visual learningGO:0085429.7HRAS, KIT
8positive regulation of tyrosine phosphorylation of Stat5 proteinGO:0425239.6KIT, JAK2
9positive regulation of MAP kinase activityGO:0434069.5FLT3, HRAS
10cell maturationGO:0484699.5CBFB, RUNX2
11myeloid progenitor cell differentiationGO:0023189.5KIT, FLT3, RUNX1
12hemopoiesisGO:0300979.5KIT, FLT3, RUNX1
13positive regulation of MAPK cascadeGO:0434109.5FLT3, KIT, HRAS
14positive regulation of tyrosine phosphorylation of Stat3 proteinGO:0425179.5KIT, JAK2
15erythrocyte differentiationGO:0302189.5JAK2, KIT
16positive regulation of sequence-specific DNA binding transcription factor activityGO:0510919.3KIT, JAK2
17positive regulation of phosphatidylinositol 3-kinase signalingGO:0140689.2KIT, JAK2, FLT3
18peptidyl-tyrosine phosphorylationGO:0181089.2KIT, JAK2, FLT3
19protein autophosphorylationGO:0467779.2FLT3, JAK2, KIT
20cytokine-mediated signaling pathwayGO:0192219.1FLT3, JAK2, KIT
21osteoblast differentiationGO:0016499.1CBFB, RUNX2
22positive regulation of cell migrationGO:0303359.1HRAS, KIT, JAK2
23activation of MAPKK activityGO:0001869.0HRAS, JAK2
24negative regulation of cell proliferationGO:0082858.8HRAS, JAK2, FLT3
25positive regulation of cell proliferationGO:0082848.1RUNX2, FLT3, JAK2, KIT, HRAS

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards/GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1transmembrane receptor protein tyrosine kinase activityGO:0047149.6FLT3, KIT
2repressing transcription factor bindingGO:0704919.3RUNX2, RUNX1
3phosphatidylinositol 3-kinase bindingGO:0435489.3JAK2, FLT3
4protein homodimerization activityGO:0428039.2KIT, FLT3, RUNX1
5protein tyrosine kinase activityGO:0047139.0KIT, JAK2
6ATP bindingGO:0055247.9KIT, JAK2, FLT3, RUNX2, RUNX1
7protein bindingGO:0055156.9RUNX1, RUNX2, FLT3, JAK2, CBFB, KIT

Products for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section
  • Antibodies
  • Proteins
  • Lysates

Sources for Core Binding Factor Acute Myeloid Leukemia

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet